Art. -Nr.: HY-N2413

Gomisin D

Kundenbewertung

Based on 1 Customer Validation

Gomisin D is an orally active lignan that binds to PDGFRβ with a K_d of 10 μM. By targeting PDGFRβ to regulate signaling pathways, Gomisin D inhibits the activation and proliferation of hepatic stellate cells and promotes their apoptosis, thereby ameliorating hepatic fibrosis. Gomisin D exhibits multiple activities such as photoprotection, antimelanogenesis, antioxidant effects, and hypoglycemic activity. Gomisin D can be used in studies related to diabetes, Alzheimer's disease, and hepatic fibrosis.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.56%
CAS. Nr.: 60546-10-3
Formel: C₂₈H₃₄O₁₀
Molecular Weight:530.56

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Gomisin D Chemical Structure

CAS. Nr.: 60546-10-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

UDP-Glucuronosyltransferases^[1]

Alle PDGFR Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Alle COX Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
C8166	CC₅₀	185.7 μM Compound: 23	Cytotoxicity against human C8166 cells after 3 days by MTT assay Cytotoxicity against human C8166 cells after 3 days by MTT assay	[PMID: 23738539]
C8166	EC₅₀	9.8 μM Compound: 23	Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect after 3 days by Syncytia Assay	[PMID: 23738539]

In Vitro

Gomisin D (10-80 μM; 25 h) enhances the viability and reduces the cytotoxicity of HaCaT keratinocytes irradiated with UVA and UVB, and inhibits intracellular ROS generation^[1].
Gomisin D (30 μM; 25 h) significantly inhibits apoptosis of UVA- and UVB-irradiated HaCaT keratinocytes^[1].
Gomisin D (10-80 μM; 49 h) dose-dependently inhibits α-MSH-induced tyrosinase activity^[1].
Gomisin D (30 μM; 49 h) significantly downregulates the mRNA and protein expression of α-MSH-induced melanogenesis-related factors MITF, tyrosinase, TRP-1 and TRP-2, as well as the phosphorylation of PKA and CREB, in B16F10 melanocytes^[1].
Gomisin D (20-80 μM; 48 h) inhibits the activation of T6, LX-2 and primary mouse hepatic stellate cells by targeting PDGFRβ^[3].
Gomisin D (40 μM) inhibits the downstream signaling pathways (p38, AKT, ERK pathways) of PDGFRβ in HSC-T6 cells by targeting PDGFRβ^[3].
Gomisin D (5-80 μM) dose-dependently inhibits PDGF-BB-induced activation, proliferation, and PDGF-BB/PDGFRβ pathway signaling in LX-2 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

HaCaT keratinocytes (UVA or UVB irradiated)
Concentration:

10, 20, 30, 40 and 80 μM
Incubation Time:

1 h pre-incubation, 24 h post-irradiation incubation
Result:

Improved viability of UVA- and UVB-irradiated HaCaT keratinocytes in a dose-dependent manner at 10, 20, 40, 80 μM.
Significantly increased viability and reduced LDH release in UVA- and UVB-irradiated HaCaT keratinocytes at 30 μM, compared to respective irradiated only groups.

Parmacokinetics

Species	Dose	Route	AUC_0-t	AUC_0-∞	MRT_0-t	MRT_0-∞	T_1/2	T_max	CL	V	C_max	Bioavailability
Rat^[2]	5 mg/kg	i.v.	3136.2 μg/L·h	3261.1 μg/L·h	6.0 h	6.9 h	5.0 h	0.083 h	1.6 L/h/kg	11.2 L/kg	539.5 μg/L	/
Rat^[2]	50 mg/kg	i.g.	32795.6 μg/L·h	35091.7 μg/L·h	7.8 h	10.6 h	5.6 h	3.0 h	1.5 L/h/kg	13.3 L/kg	2575.2 μg/L	107.6 %

In Vivo

Gomisin D (25-50 mg/kg; i.g.; 4 weeks) alleviates CCl₄-induced hepatic fibrosis in male BALB/c mice^[3].
Gomisin D (50 mg/kg; p.o.; 30 days) causes no observable histotoxicity in male BALB/c mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c (male, 6-8 weeks old, 18-22 g, CCl₄-induced hepatic fibrosis)^[3]
Dosage:

25 mg/kg; 50 mg/kg
Administration:

i.g.; once daily; 4 weeks
Result:

Improved survival status and liver morphology.
Reduced hepatocyte necrosis, preserved hepatic lobule structure, and decreased collagen deposition in both dose groups, with more significant improvements in the 50 mg/kg group.
Significantly reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels compared to the model group in both dose groups.
Significantly decreased mRNA and protein levels of α-smooth muscle actin (α-SMA) and collagen I in liver tissue and isolated primary hepatic stellate cells (HSCs) from both dose groups, with the 50 mg/kg group showing greater reductions.
Significantly decreased protein levels of phosphorylated AKT (p-AKT), phosphorylated ERK (p-ERK), and phosphorylated p38 (p-p38) in liver tissue from both dose groups.
Significantly decreased mRNA levels of inflammatory factors IL-1β, IL-6, TNF-α, TGF-β, and COX-2 in liver tissue from both dose groups.

Chemical Information

CAS. Nr. 60546-10-3
Appearance Solid
Molecular Weight 530.56
Formel C₂₈H₃₄O₁₀
Color Off-white to light yellow
SMILES

COC1=C(OC)C(OC)=CC2=C1C3=C(CC(C)C(C)(O)C2O4)C=C(OCO5)C5=C3OCC(C)C(C)(O)C4=O
Structure Classification
- Phenylpropanoids
- Lignans
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (188.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8848 mL

9.4240 mL

18.8480 mL

5 mM

0.3770 mL

1.8848 mL

3.7696 mL

10 mM

0.1885 mL

0.9424 mL

1.8848 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (4.71 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (290 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Jeon JS, et al. Comparative study of the photo‑protective and anti‑melanogenic properties of gomisin D, J and O. Mol Med Rep. 2022;25(1):8. [Content Brief]

[2]. Zheng X, et al. A Rapid UPLC-MS Method for Quantification of Gomisin D in Rat Plasma and Its Application to a Pharmacokinetic and Bioavailability Study. Molecules. 2019;24(7):1403. Published 2019 Apr 10. [Content Brief]

[3]. Wang R, et al. Gomisin D alleviates liver fibrosis through targeting PDGFRβ in hepatic stellate cells. Int J Biol Macromol. 2023;235:123639. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8848 mL	9.4240 mL	18.8480 mL	47.1200 mL
	5 mM	0.3770 mL	1.8848 mL	3.7696 mL	9.4240 mL
	10 mM	0.1885 mL	0.9424 mL	1.8848 mL	4.7120 mL
	15 mM	0.1257 mL	0.6283 mL	1.2565 mL	3.1413 mL
	20 mM	0.0942 mL	0.4712 mL	0.9424 mL	2.3560 mL
	25 mM	0.0754 mL	0.3770 mL	0.7539 mL	1.8848 mL
	30 mM	0.0628 mL	0.3141 mL	0.6283 mL	1.5707 mL
	40 mM	0.0471 mL	0.2356 mL	0.4712 mL	1.1780 mL
	50 mM	0.0377 mL	0.1885 mL	0.3770 mL	0.9424 mL
	60 mM	0.0314 mL	0.1571 mL	0.3141 mL	0.7853 mL
	80 mM	0.0236 mL	0.1178 mL	0.2356 mL	0.5890 mL
	100 mM	0.0188 mL	0.0942 mL	0.1885 mL	0.4712 mL

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Gomisin D

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Alle PDGFR Isoform-spezifische Produkte anzeigen

Alle p38 MAPK Isoform-spezifische Produkte anzeigen

Alle Akt Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Alle COX Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität